Please select a community
Automation & Microfluidics
Biologics & Bioprocessing
Chemical Process Scale Up
Food & Beverage Analysis
Forensic Science & Clinical Toxicology
Genotyping & Gene Expression
LIMS & ELNs
Metabolomics & Lipidomics
Molecular & Clinical Diagnostics
Next Gen Sequencing
Stem Cells, Cellular Therapy & Biobanking
Become a Member
Add My Services
FDA, EMA Extend Licenses for Aptiv Solutions ADDPLAN® Software
Wednesday, January 08, 2014
FDA purchases novel ADDPLAN® DF Software for improved evaluation of Phase II dose-finding trials.
EyeTechCare Doubles the Number of Health Care Facilities in France with the EyeOP1 Device
Thursday, January 02, 2014
The EyeOp1 device is now available in ten centers across France, with this figure expected to double in 2014.
TELOS MicroPlate™ from Kinesis – a versatile 96-well SPE format for small volume biological fluid samples
Monday, December 16, 2013
The TELOS MicroPlate™ is a versatile 96-well plate for the extraction of drug molecules from small volume biological fluid samples.
New UK mHealth Congress Announced for 2014
Tuesday, November 19, 2013
MCT-Congress will bring together key influencers to drive the business of mHealth in clinical research.
Phenom-World Launches the New Particlemetric Software for Fully Automated Inspection and Analysis of Particles
Tuesday, November 12, 2013
With the introduction of the ParticleMetric software, the visualization and analysis of particles are easier than ever before with the Phenom desktop SEM.
Nov 20 Best Practices IV: Preclinical Outsourcing Program/Simulcast
Monday, November 11, 2013
Preclinical outsourcing program/simulcast at Ocean Place in Long Branch, NJ, and via Webinar.
Quotient Clinical at AAPS 2013
Friday, November 08, 2013
AAPS annual meeting and exposition to be held in San Antonio, Texas, from the 10th to the 14th of November.
Aesica Introduces Aseptic Micro Dosing Capabilities at Nottingham Site
Tuesday, November 05, 2013
New technology (3P Fill2Weight) reduces development cycle and can be used with capsules, vials, inhalers, injectables, blisters and even high potents.
Aptiv Solutions ADDPLAN® DF is the First Validated Software to Use MCP-Mod Methodology
Thursday, October 31, 2013
MCP-Mod methodology was recently qualified by EMA for reducing bias and error in dose finding clinical trials.
Showing Results 51 - 60 of 309
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Advertise On This Site
Terms & Conditions
©2015 Technology Networks
, all rights reserved.
Latest presentations and webinars
2,400+ scientific and medical posters
3,700+ scientific videos
JOIN TECHNOLOGY NETWORKS PREMIUM FREE!